MTOR and autosomal dominant polycystic kidney disease: The identification of the role and function of PC-1 in the mTOR pathway provides additional targets, including AKT, whose modulation either singly, or in combination with rapamycin, may contribute to alternative therapeutic strategies in the treatment of ADPKD.